SouthernSun Asset Management, LLC, an investment management firm, released its “SouthernSun Small Cap Strategy” third quarter ...

Analyst Michael Petusky of Barrington maintained a Buy rating on US Physical Therapy (USPH – Research Report), retaining the price target ...

Nkarta faces competition from FATE's FT522, a CAR-NK cell therapy that might be used with reduced or no conditioning ...

Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. See why I rate ...

Bank of America Securities analyst Joanna Gajuk maintained a Hold rating on US Physical Therapy (USPH – Research Report) today. The ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator instructions ... On rare occasions, our expert team of analysts issues a “Double Down” stock ...

U.S. Physical Therapy, Inc. (“USPH”) (NYSE ... USPH also has an industrial injury prevention business which provides onsite services for clients’ employees ...

Sage and its collaborator, Biogen, are focused on the goal of establishing ZURZUVAE as the first line therapy and standard of care for women with postpartum depression (PPD). As of the third quarter ...

Ended Q3 2024 with $403.4 Million in Cash, Cash Equivalents and Investments; Cash Runway Continues to be Projected into 2H ...

MaxCyte now expects full year 2024 core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year ...

Q3 2024 Earnings Call Transcript October 30, 2024Day One Biopharmaceuticals, Inc. beats earnings expectations.